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Abstract. Background: TSU-68 is a multikinase inhibitor
that targets platelet-derived growth factor receptors
(PDGFRs). In the present study, we evaluated the effect of
TSU-68 on the tumor-microenvironment interaction in
hepatocellular carcinoma (HCC). Materials and Methods:
HCC and fibroblast cell lines (HuH7, Hep3B, HuH1 and
WI-38) were used to evaluate their interactions. Cancer
characteristics were evaluated by spheroid formation and
tumorigenicity in immunodeficient mice. Time-lapse image
analysis was performed to monitor cell motility. Results:
Although PDGFA was abundantly expressed, PDGFR-α was
predominantly located in the cytoplasm and was not
functional in HuH7 cells. Co-culture experiments
demonstrated that HCC cells induced phosphorylation of
PDGFR-α in WI-38 fibroblasts and that stimulated
fibroblasts, in turn, boosted the spheroid formation capacity
of HCC cells. TSU-68 inhibited phosphorylation of PDGFR-
α in WI-38 cells and suppressed the growth of
subcutaneously co-injected HuH7/WI-38 tumor xenografts.
Conclusion: TSU-68 inhibits stromal PDGF signaling
activated by cancer cells and suppresses HCC growth.
Hepatocellular carcinoma (HCC), one of the most common
malignancies worldwide, has a dismal outcome (1). HCC is
considered a heterogeneous disease in terms of
morphology, clinical behavior and response to treatment
(2). This heterogeneity has been considered to be related to
the diversity of the genetic/epigenetic alterations that
accumulate in the cancer cells; however, recent evidence
has shed new light on the role of the microenvironment in
the regulation of the heterogeneous nature of HCC,
potentially through paracrine activation of various signaling
pathways (3). The HCC microenvironment is composed of
diverse stromal cells including lymphocytes, macrophages,
stellate cells, fibroblasts and endothelial cells. These cells
produce various cytokines, chemokines and growth factors,
such as interleukin (IL)-6, IL-8, Wnt, fibroblast growth
factors , platelet-derived growth factors (PDGFs), vascular
endothelial growth factors (VEGFs) and transforming
growth factor (TGF)-β that activate downstream signaling
pathways in cancer cells.
Sorafenib is a multikinase inhibitor targeting the RAF,
RET, VEGFR and c-Kit pathways. It has been shown in two
large independent clinical cohorts to enhance overall survival
(by a median of approximately 3 months) in advanced HCC
patients compared to placebo control (4, 5). Because tumor
shrinkage has rarely been observed in these trials, the
effectiveness of sorafenib is considered to be mainly related
to anti-angiogenesis effects through inhibition of VEGFR2
signaling in tumor endothelial cells. However, recent
evidence has demonstrated that some HCC patients exhibit
complete/partial responses after sorafenib treatment.
Interestingly, some of these HCC specimens showed an
amplification of fibroblast growth factors 3/4 or VEGFA that
may potentially activate stromal cells, such as endothelial
cells or fibroblasts, which, in turn, may activate growth
signaling in cancer cells through production of growth
factors, such as hepatocyte growth factor (6, 7). Therefore,
the effectiveness of a molecular-targeted therapy in HCC
may be determined, at least in part, by an interaction
between the tumor and its microenvironment; however, the
role of the microenvironment in HCC chemosensitivity
remains to be elucidated.
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The PDGF signaling system contributes to tumor angio -
genesis and vascular remodeling in solid tumors (8). TSU-68
is a multikinase inhibitor that targets PDGFRs, as well as
VEGFR2. The efficacy of TSU-68 is currently being
investigated in various solid cancers, including breast, gastric,
lung and colorectal (9-12). In addition, a recent phase I/II
study has suggested promising preliminary efficacy with a
high safety profile in patients with advanced HCC (13). The
inhibitory effect of TSU-68 on PDGF receptor phospho -
rylation at low concentrations suggests its utility in HCC with
activated PDGF signaling. Indeed, PDGFRs are expressed in
a subset of HCCs (14). However, the role of PDGF signaling
in HCC development remains to be fully elucidated (15).
Furthermore, it is unclear how and in which type of cells
PDGF signaling is activated and how these cells participate
in the pathogenesis of HCC (16). Accordingly, in the present
study, we evaluated the expression of PDGF and PDGFRs in
HCC and fibroblast cell lines to clarify the role of PDGF
signaling in HCC. We further evaluated the effects of TSU-
68 on the interaction between cancer cells and fibroblasts in
vivo and used an in vitro co-culture system to evaluate the
molecular mechanisms of TSU-68 action on HCC.
Materials and Methods
Cell lines and reagents. The human HCC cell lines HuH1 and HuH7
were obtained from the Japanese Collection of Research Bioresources
(Ibaraki, Osaka, Japan). Hep3B was obtained from the American Type
Culture Collection (Manassas, VA, USA). WI-38 fibroblasts were also
obtained from the American Type Culture Collection. All cells were
cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(FBS; Invitrogen). TSU-68 was provided by Taiho Pharmaceutical
(Taiho Pharmaceutical Co., Ltd., Tokyo, Japan).
Quantitative reverse transcription-polymerase chain reaction (qRT-
PCR). Total RNA was extracted using TRIzol (Invitrogen) according
to the manufacturer’s instructions. The expression of selected genes
was determined in triplicate using an Applied Biosystems 
7900HT Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). The following probes were used for 
qRT-PCR: PDGFA, Hs00964426_m1; PDGFB, Hs00234042_m1;
PDGFC, Hs00910225_s1; PDGFRA, Hs00183486_m1; PDGFRB,
Hs01019589_m1; TGFB1, Hs00171257_m1; and 18S,
Hs99999901_s1 (Applied Biosystems).
Western blotting. Whole-cell lysates were prepared using RIPA
lysis buffer. Mouse monoclonal antibody to human PDGFR-α
clone D13C6 (Cell Signaling Technology, Danvers, MA, USA),
mouse monoclonal antibody to human PDGFR-β clone C82A3
(Cell Signaling Technology), mouse monoclonal antibody to
human phospho-PDGFR-α (Thr754) clone 23B2 (Cell Signaling
Techno logy) and mouse monoclonal anti-β-actin antibody
(Sigma-Aldrich, St. Louis, MO, USA) were used. Immune
complexes were visualized by enhanced chemiluminescence
(Amersham Biosciences Corp., Piscataway, NJ, USA), as
described previously (17). 
Cell proliferation assay. Single-cell suspensions of 2×103 cells were
seeded in 96-well plates and cell proliferation was evaluated in
quadruplicate using a Cell Titer 96 Aqueous kit (Promega, Madison,
WI, USA). TSU-68 was dissolved in DMSO and cells were treated
with 0.1% DMSO (control) or 10 μM TSU-68 (0.1% final
concentration) for 72 h.
Fluorescence-activated cell sorting analyses. For fluorescence-
activated cell sorting (FACS), HuH7 cells were trypsinized, washed
and re-suspended in Hank’s Balanced Salt Solution (Lonza, Basel,
Switzerland) supplemented with 1% HEPES and 2% FBS.
Intracellular PDGFR-α protein levels were examined using a
Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences,
San Jose, CA, USA), as described previously (18). Permeabilized or
untreated cells were incubated with phycoerythrin (PE)-conjugated
anti-human CD140a (PDGFR-α) antibody clone 16A1 (BioLegend,
San Diego, CA, USA) on ice for 30 min. Labeled cells were analyzed
using a FACSCalibur flow cytometer (BD Biosciences).
Spheroid formation assay. For co-culture experiments, 1×105 HuH7 or
WI-38 cells were harvested in Cell Culture Inserts (BD Biosciences)
for 24 h. Inserts were then washed twice with phosphate-buffered
saline (PBS). Single-cell suspensions of 2×103 HuH7 cells were
seeded in 6-well Ultra-Low Attachment Plates (Corning, Corning, NY,
USA). Cells were incubated with culture media containing 0.1%
DMSO (control) or 10 μM TSU-68 (0.1% final concentration). Co-
culture cell inserts were transferred to Ultra-Low Attachment Plates
(Corning) and incubated for 14 days. The number of spheroids (>200
μm in diameter) was measured in triplicate in each group.
Wound-healing assay and time-lapse image analysis. A wound-
healing assay was performed using μ-Slide 8-well chambers and
culture inserts (Ibidi, Martinsried, Germany) as described
previously (19). Briefly, 2×103 HuH7 and WI-38 cells were
labeled with the lipophilic fluorescence tracer DiO (indicated as
green) or DiD (indicated as blue) and incubated in a culture insert
in μ-Slide 8-well chambers overnight. Silicone inserts were
detached and the culture media was replaced with DMEM
containing 10% FBS and 0.1% DMSO (control) or 10 μM TSU-
68. Immediately after the medium change, cells were cultured at
37˚C in 5% CO2 and time-lapse images were captured for 48 h
using a CSU-X1 spinning disk confocal (Yokogawa, Tokyo,
Japan) and Andor iXon3 EMCCD camera system (Andor
Technology, Belfast, UK). Images were analyzed by iQ Software
(Andor Technology).
Tumorigenicity in non-obese diabetic/severe combined immuno -
deficient (NOD/SCID) mice. Cells (1×105 HuH7 and 1×105 WI-38
cells) were mixed and suspended in 200 μl of 1:1 DMEM and
Matrigel (BD Biosciences) and subcutaneously injected into 6-
week-old NOD/SCID mice (NOD/NCrCRl-Prkdcscid) (Charles River
Laboratories, Wilmington, MA, USA). Control vehicle (aqueous
carboxymethylcellulose containing 0.9% (w/v) benzyl alcohol, 0.4%
(w/v) Tween 80, and 9 mg/ml sodium chloride) or TSU-68 solution
(400 mg/kg) was orally ingested twice daily on days 16-20 and 23-
28. The sizes and incidence of subcutaneous tumors were recorded
as previously described (18). All mice were euthanized on day 31
and tumors were formalin-fixed and paraffin-embedded and used for
immunohistochemistry. The protocol was approved by the
Kanazawa University Animal Care and Use Committee.
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Figure 1. PDGFR expression in HCC. A, qRT-PCR analysis of PDGFRA and PDGFRB expression in Hep3B, HuH7 and HuH1 cells. B, Western
blotting analysis of PDGFR-α and -β in Hep3B, HuH7 and HuH1 cells. C, MTS assay of HuH1, HuH7 and Hep3B cells treated with 0.1% DMSO
or 10 μM TSU-68. D, FACS analysis of HuH7 cells stained with PE-conjugated anti-PDGFR-α antibodies. Cells were fixed and permeabilized to
stain intracellular PDGFR-α. 
Immunohistochemistry analysis. Immunohistochemistry (IHC) was
performed using mouse anti-Smad3L (Ser 208/213 phosphorylated)
rabbit antibodies (Takara Bio Inc., Ohtsu, Japan) and Envision+ kits
(Dako USA, Carpinteria, CA, USA), as described previously (18). 
Statistical analyses. Student’s t-tests were performed with the
GraphPad Prism software 5.0 (GraphPad Software, San Diego, CA,
USA) to compare the various test groups assayed by spheroid assays
and qRT-PCR analysis.
Results
PDGFs are expressed but their receptors are absent or not
functional in HCC cell lines. To explore the role of PDGF
signaling in HCC, we evaluated the expression of genes
encoding PDGF receptors (PDGFRA and PDGFRB) in three
human HCC cell lines (Hep3B, Huh1 and Huh7) by qRT-
PCR (Figure 1A). We identified a marked expression of
ANTICANCER RESEARCH 35: 1423-1432 (2015)
1426
Figure 2. Activation of PDGF signaling in fibroblasts by HCC co-culture. A, qRT-PCR analysis of PDGFRA and PDGFRB expression in Hep3B,
HuH7 and WI-38 fibroblasts. B, qRT-PCR analysis of PDGFA, PDGFB and PDGFC expression in Hep3B, HuH7 and HuH1 HCC cells, as well as
WI-38 fibroblasts. C, Western blot analysis of HuH7 and WI-38 cells treated with 50 ng/ml PDGF-AA with or without 10 μM TSU-68. D, Western
blot analysis of WI-38 cells co-cultured with WI-38 or HuH7 cells treated with or without 10 μM TSU-68 for 48 h.
PDGFRA and PDGFRB genes in HuH7 cells compared to
HuH1 and Hep3B cells. We further evaluated the protein
expression of PDGFR-α and PDGFR-β by western blotting,
finding that PDGFR-α and PDGFR-β protein was only
detectable in HuH7 cells (Figure 1B). PDGFR-α was more
abundantly expressed than PDGFR-β in HuH7 cells,
consistent with a previous report showing the dominant
expression of PDGFR-α in primary HCCs (14). We
evaluated the effect of TSU-68 on these cell lines, expecting
strong chemosensitivity to TSU-68, specifically in HuH7
cells, because TSU-68 inhibits phosphorylation of PDGFRs.
However, we identified a reduction in cell proliferation of up
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Figure 3. TSU-68 ameliorates malignant features of HCC induced by fibroblasts with activation of PDGF signaling. A, Wound-healing assay of
HuH7 (green) and WI-38 cells (blue) treated with or without 10 μM TSU-68 for 48 h. Note the high green background signals of TSU-68-treated cells
due to the autofluorescence of TSU-68. B, Spheroid formation assay of HuH7 cells co-cultured with HuH7 cells (panels a and c) or WI-38 fibroblasts
(panels b and d) treated with (panels c and d) or without (panels a and b) 10 μM TSU-68 (scale bar: 200 μm). C, Number of spheroids obtained
from 2,000 HuH7 cells co-cultured with HuH7 or WI-38 cells and treated with or without 10 μM TSU-68. The number of spheroids with a size of
200 μm or more was counted. D, qRT-PCR analysis of TGFB1 in WI-38 cells co-cultured with WI-38 or HuH7 cells and treated with or without 10
μM TSU-68.
to 20% when all cell lines were treated with 10 μM TSU-68
(Figure 1C). We could not detect differential chemo -
sensitivity to TSU-68 between HuH1 and HuH7 cells
irrespective of a 20,000-fold difference in PDGFRA expres -
sion and a 10-fold difference in PDGFRB expression.
We investigated the subcellular localization of PDGFR-α
in HuH7 cells by FACS analysis. Surprisingly, most PDGFR-
α expressed in HuH7 cells was located in the cytoplasm and
not in the cell membrane (Figure 1D) suggesting that most
PDGFR-α expressed in HuH7 cells cannot bind to PDGF
ligands. Similar results were obtained for PDGFR-β in HuH7
cells (data not shown). These data suggest that even if
PDGFRs are detected in some HCCs, PDGFRs may not
always be located at the cell membrane and be in a
functioning state.
HCC cell lines produce PDGFs and activate PDGF signaling
in fibroblasts in a paracrine manner. We next examined the
expression of PDGFRs in WI-38 fibroblasts because
fibroblasts are the major stromal cells in liver cirrhosis tissues
and HCC. By qRT-PCR, PDGFRA expression was detected
at a comparable level to that of HuH7 cells, while PDGFRB
was more abundantly expressed in WI-38 cells (Figure 2A).
We also evaluated the expression of PDGF ligands (PDGFA,
PDGFB and PDGFC) in HCC cell lines and WI-38 cells.
Interestingly, PDGFA, PDGFB and PDGFC were strongly
expressed in Hep3B and HuH7 cells compared to HuH1 cells
(Figure 2B), even though PDGFRs were not detected or were
not functional in these cells. Furthermore, the expression of
PDGF ligand genes was extremely low in WI-38 cells,
irrespective of the abundant expression of PDGFRs. These
data prompted us to hypothesize that HCC cells produce
PDGF ligands but do not stimulate themselves in an autocrine
manner. Rather, PDGF ligands produced by HCC activate
stromal fibroblasts in a paracrine manner and stimulated
fibroblasts, in turn, produce growth factors that may enhance
the malignant nature of HCC cells.
We evaluated the effect of recombinant PDGF ligands on
the phosphorylation of PDGFRs in HuH7 and WI-38 cells.
Enhancement of PDGFR-α phosphorylation was clear in
WI-38 cells but not in HuH7 cells (Figure 2C). PDGF-AA
(50 ng/ml) could not augment the proliferation of HuH7
cells (data not shown). TSU-68 suppressed PDGFR-α
phospho rylation in WI-38 cells but had little effect in HuH7
cells. We could not appropriately evaluate PDGFR-β
phosphorylation by western blotting in HuH7 and WI-38
cells (data not shown) due to a lack of antibodies suitable
for this approach. These data are in line with our hypothesis
described above, namely, that PDGF ligands expressed in
HCC may mainly activate stromal fibroblasts. We further
evaluated the interaction of HuH7 and WI-38 cells using a
co-culture system. Phosphorylation of PDGFR-α was
enhanced in WI-38 fibroblasts when they were co-cultured
with HuH7 cells compared to those co-cultured with WI-38
cells (Figure 2D). This enhanced phosphorylation was
attenuated by TSU-68 treatment.
Fibroblasts stimulated by PDGFs produce TGF-β and
regulate hepatocellular carcinoma growth. We evaluated the
motility of WI-38 fibroblasts co-cultured with HuH7 cells
treated with DMSO control or 10 μM TSU-68 using a
wound-healing assay and time-lapse image analysis (Figure
3A). Cell motility of WI-38 fibroblasts was suppressed by
TSU-68 treatment compared to control suggesting a role for
PDGF signaling in the activation of fibroblast cell motility.
We further evaluated the role of fibroblasts on the spheroid
formation of HuH7 cells using a co-culture system.
Spheroid formation capacity was significantly enhanced
when HuH7 cells were co-cultured with WI-38 cells
compared with those co-cultured with HuH7 cells (p=0.025)
(Figure 3B panels a and b and Figure 3C) suggesting that
WI-38 secretes certain growth factors that enhance the
spheroid formation capacity of HuH7 cells. TSU-68
treatment had no effect on the suppression of spheroid
formation in HuH7 cells when co-cultured with HuH7 cells
(Figure 3B panel c). However, TSU-68 treatment modestly
suppressed the spheroid formation capacity of HuH7 cells
boosted by co-culture with WI-38 fibroblasts (p=0.05)
(Figure 3B panel d and Figure 3C).
As a candidate growth factor secreted by stimulated
fibroblasts, we evaluated the expression of TGFB1 because
we have previously found that endogenous TGFB1
expression is very low in HuH7 cells and because
exogenous supple mentation with TGF-β enhances cell
motility and distant organ metastasis of HuH7 cells (19).
Interestingly, a three-fold increase in TGFB1 expression was
observed when WI-38 cells were co-cultured with HuH7
cells compared with those co-cultured with WI-38 cells
(Figure 3D). Furthermore, this enhancement was abolished
by TSU-68 treatment suggesting that PGDF ligands secreted
by HuH7 cells may be responsible for this induction of
TGFB1 in WI-38 cells.
TSU-68 inhibits PDGF signaling in fibroblasts and sup -
presses hepatocellular carcinoma growth. Finally, we
explored the effect of TSU-68 in vivo using a subcutaneous
xenotransplantation model in immunodeficient mice. We
injected HuH7 and WI-38 cells (1×105 each per mice)
together into a subcutaneous lesion of NOD/SCID mice to
clarify the role of PDGF signaling in the HCC-fibroblast
interaction. We initiated oral ingestion of TSU-68 (n=4) or
control vehicle (n=4) 2 weeks after inoculation to clarify the
effect of TSU-68 in the early phase of subcutaneous tumor
formation. By day 31, three out of four control mice had
developed subcutaneous tumors, whereas only one out of
four TSU-68-treated mice had developed tumors. Moreover,
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the tumor volume differences were statistically significant
(p=0.05) (Figure 4A).
We identified nuclear accumulation of phosphorylated
Smad3 in the tumor in the control group suggesting activation
of TGF-β signaling in HuH7 cells when co-injected with WI-
38 (Figure 4B, left panel). We could not detect nuclear
accumulation of phosphorylated Smad3 in the tumors that
developed in TSU-68-treated mice (Figure 4B, right panel).
Taken together, these data suggest a role for PDGF signaling
in HCC (Figure 5). HCC cells secrete PDGF ligands and
PDGF signaling is activated in stromal fibroblasts to produce
TGF-β, which, in turn, activates TGF-β signaling in HCC in a
paracrine manner. TSU-68 may target the activated stromal
fibroblasts and, therefore, may be most effective in HCC with
abundant stromal fibroblasts such as scirrhous HCC.
Discussion
Recent evidence suggests the pivotal roles of stromal cells in
tumor initiation, promotion, progression and chemoresistance
in several cancers (3). PDGFs and PDGFRs are frequently
expressed in various cancers and may regulate tumor growth,
Hara et al: PDGF Signaling in HCC Microenvironment 
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Figure 4. TSU-68 suppressed the HCC growth in vivo. A, Tumorigenicity of 1×105 HuH7 cells co-injected with 1×105 WI-38 cells in NOD/SCID mice.
Mice were treated with TSU-68 (400 mg/kg, twice daily) or control vehicle for 2 weeks. B, Representative photomicrographs of subcutaneous tumors
stained with anti-phospho-Smad3 antibodies (scale bar: 100 μm). The black arrow indicates nuclear accumulation of phospho-Smad3 in HuH7 cells.
Figure 5. Schematic of the cancer cell-fibroblast interaction and PDGF signaling in HCC. HCC cells produce PDGF ligands and phosphorylate
PDGFRs in fibroblasts. Activated fibroblasts produce TGF-β and phosphorylate Smad3 in HCC cells. TSU-68 inhibits PDGFR phosphorylation in
fibroblasts, suppresses the expression of TGF-β and inhibits HCC growth.
invasiveness and chemoresistance (8). In this study, we found
that, although PDGFs are abundantly expressed, PDGFRs are
expressed at quite low levels or are not functional in three
HCC cell lines. PDGFs activate PDGFRs in WI-38
fibroblasts and stimulated fibroblasts produce TGF-β and
regulate the aggressive nature of HuH7 cells. This is the first
study to demonstrate that TSU-68, a kinase inhibitor of
PDGFRs, mainly acts on stromal fibroblasts to block the
production of TGF-β and inhibit HCC growth.
The PDGF family consists of four structurally-related
single polypeptides, encoded by PDGFA, PDGFB,
PDGFC and PDGFD that form five functional homo- or
heterodimers: PDGF-AA, PDGF-BB, PDGF-AB, PDGF-
CC and PDGF-DD. PDGFRs are cell surface tyrosine
kinase receptors composed of PDGFR-α and PDGFR-β,
encoded by PDGFRA and PDGFRB, that form homo- or
heterodimers: PDGFR-αα, PDGFR-αβ and PDGFR-ββ. A
previous study investigated the expression of PDGFR-α,
-β and its ligand genes PDGFA, PDGFB and PDGFC in
fetal liver and HCC, finding the expression of PDGFR-α
in 10 of 22 HCCs by western blotting and 17 of 21 HCCs
by IHC (14). Although we could not reliably evaluate the
activation of PDGFR-β (phospho-PDGFR-β), we
identified the over-expression of PDGFR-α in one out of
three HCC cell lines. However, most PDGFR-α protein
was located at the cytoplasm and was not functional in
HuH7 cells. Indeed, the photomicrographs of the previous
report also showed cytoplasmic PDGFR-α staining in
human HCC tissues (14). 
Because we evaluated the expression of PDGFR-α and
PDGFR-β in only three HCC cell lines and one fibroblast
cell line, we cannot conclude that PDGF signaling is
generally defective in human HCC. Besides, we could not
reliably evaluate the PDGFR-β status due to the lack of
available appropriate antibodies, including those used in the
previous publication. Further studies are required to evaluate
the function of PDGFRs expressed in a subset of HCCs.
Our data suggest that HCC cell lines produce PDGF
ligands and activate stromal fibroblasts. TSU-68
suppressed PDGFR-α phosphorylation, inhibited the
expression of TGFB1 in vitro and suppressed Smad3
phosphorylation and tumor growth in vivo. Although the
tumor suppressive effects of TSU-68 may be mainly
related to anti-angiogenic effects exerted by inhibiting
VEGFR2 in vivo, our data demonstrated that TSU-68 also
suppressed PDGFR pho sphorylation in stromal fibroblasts
and inhibited TGF-β production. A previous study demon -
strated the activation of TGF-β signaling in scirrhous HCC
with abundant fibrous stromal component and poor pro -
gnosis (20). TSU-68 may, thus, effectively treat this HCC
subtype; however, further studies are required to evaluate
the efficacy of TSU-68 in various HCC subtypes with
distinct molecular features and prognosis.
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